Complete Genomics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: October 15, 2016
Pages: 50
US$ 499.00
Complete Genomics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Complete Genomics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Complete Genomics, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Complete Genomics, Inc. and its competitors. This provides our Clients with a clear understanding of Complete Genomics, Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Complete Genomics, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Complete Genomics, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Complete Genomics, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Complete Genomics, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Complete Genomics, Inc. business.

About Complete Genomics, Inc.

Complete Genomics, Inc., a life sciences company, develops and commercializes a DNA sequencing platform for human genome sequencing and analysis.

Human Genome Sequencing Platform Technology

The company’s genomics analysis platform combines its proprietary human sequencing technology with informatics and data management software to provide customers with data that is ready to be used for genome-based research.

The company's human genome sequencing service would be used in applications, such as cancer research; mendelian disease research; rare variant disease research; and clinical trial optimization. In addition to these research studies, its clinical applications would include companion diagnostics; cancer pathology; and universal diagnostics.

Proprietary Sequencing Technology

There are two primary components of its proprietary human genome sequencing technology: DNA nanoball (DNB) arrays and combinatorial probe-anchor ligation (cPAL) reads.

DNB Arrays: The company has developed an approach to preparing fragmented DNA for reading on its sequencing instruments. Using a biochemical process for copying DNA, the company reproduces each DNA fragment in a manner that connects all of the copies together in a head-to-tail configuration, forming a long single molecule of connected nucleotides. The company has developed proprietary techniques for causing each long single molecule to consolidate, or ball up, into a small particle of DNA that is called as DNB.

cPAL Read: To read the sequence of nucleotides in each DNB, the company has developed a proprietary ligase-based DNA reading technology called cPAL. The company’s cPAL technology uses the naturally occurring ligase enzyme, which distinguishes between the A, C, T, and G nucleotides, to attach fluorescent molecules that light up with a different color for each of the four nucleotides.

High Throughput Process Automation

There are five major components of its high-throughput process automation technology: high-throughput sample preparation, high-throughput sequencing instruments, computing infrastructure, workflow automation software, and service delivery technology.

High-Throughput Sample Preparation: The company’s sample preparation technology consists of step-by-step protocols for preparing DNA for sequencing and pipetting robots that automatically execute these protocols. The company prepares genomes samples in batches of 88 and loads the samples into a 96-well plate.

High-Throughput Sequencing Instruments: The company’s sequencing instruments consist of a fluidics robot that pipettes multiple types of chemical reagents (including fluorescent molecules) onto the flow slides and an imaging system that records images of the fluorescent molecules attached to the DNA. Each sequencing instrument processes 18 flow slides at a time. Its sequencing instruments can generate between 50 and 70 gigabases of usable data from each flow slide in a 12-day run.

Computing Infrastructure: The company has built a genomic data processing facility that consists of approximately 5,000 core processors and 1,750 terabytes (a terabyte is one thousand gigabytes) of high-speed disk storage. The company’s sequencing instruments are connected to its data center by a network connection that transfers data at a rate of 30 gigabits per second.

Workflow Automation Software: The company’s workflow automation software tracks each sample from arrival at its facility to delivery of research-ready data to the customer. Sample tracking is accomplished through bar codes. Each 96-well plate of samples has a bar code, and each flow slide has a bar code.

Service Delivery Technology: The company’s cloud-based data delivery system is based on its vendor relationship with Amazon Web Services (AWS). It uploads its customers’ finished genomic data to AWS, who copies the data to hard disks and ships the hard disks to its customers. The company’s customers also can pay AWS to store their data on an ongoing basis.

Data Management Solution

There are two major components of its data management solution: assembly software and analysis software.

Assembly Software: The company has developed a proprietary approach to assembly that uses a combination of advanced data analysis algorithms and statistical modeling techniques to reconstruct the human genome from approximately two billion 70-base reads.

Analysis Software: The company is also developing a suite of additional analytical tools designed to enable its customers to analyze the data the company generates from their samples.

Customers and Markets

The company serves academic and government research centers, and biopharmaceutical companies. It operates in the United States, Canada, and Europe. Its customers include Academic Medical Center University of Amsterdam; Brigham & Women’s Hospital; Broad Institute of MIT and Harvard; Children’s Hospital of Philadelphia; Eli Lilly and Company; Erasmus Medical Centre in Rotterdam, the Netherlands; Flanders Institute for Biotechnology; Genentech, Inc.; HudsonAlpha Institute for Biotechnology; Institute of Cancer Research United Kingdom; Institute of Molecular Medicine at the University of Texas Health Science Center at Houston; Institute for Systems Biology; National Cancer Institute; Ontario Institute for Cancer Research; Pfizer Inc.; and University of North Carolina.


The company's competitors include Illumina, Inc.; Life Technologies Corporation; and Roche Diagnostics Corporation.


Complete Genomics, Inc. was founded in 2005.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Complete Genomics, Inc. Direct Competitors
5.2. Comparison of Complete Genomics, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Complete Genomics, Inc. and Direct Competitors Stock Charts
5.4. Complete Genomics, Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Complete Genomics, Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Complete Genomics, Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Complete Genomics, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Complete Genomics, Inc. Major Shareholders
Complete Genomics, Inc. History
Complete Genomics, Inc. Products
Revenues by Segment
Revenues by Region
Complete Genomics, Inc. Offices and Representations
Complete Genomics, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Complete Genomics, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Complete Genomics, Inc. Capital Market Snapshot
Complete Genomics, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Complete Genomics, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Complete Genomics, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Complete Genomics, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Complete Genomics, Inc. 1-year Stock Charts
Complete Genomics, Inc. 5-year Stock Charts
Complete Genomics, Inc. vs. Main Indexes 1-year Stock Chart
Complete Genomics, Inc. vs. Direct Competitors 1-year Stock Charts
Complete Genomics, Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Complete Genomics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: